Building on pioneering work performed during the first wave of heart-lung transplantation, Brigham and Women’s Hospital has resumed its heart-lung program and is once again performing the rare procedure.
Although there is no cure for pulmonary arterial hypertension (PAH), investigators from Brigham and Women’s Hospital are unraveling the molecular mechanisms that may control PAH’s development and progression in an effort toward finding treatments that could halt its advancement. In Science Translational Medicine, researchers shared results from a study that identifies the cancer protein NEDD9 as a critical player in disease development, with potential therapeutic implications for patients with PAH.
A study by investigators at Brigham and Women’s Hospital that models allergic lung inflammation provides new insight into how neutrophil cytoplasts can contribute to asthma severity. The results may have implications for developing drugs for people with severe asthma.
For lung cancer surgeries, should there be an imperative to use minimally invasive techniques?
Video-assisted thoracic surgery (VATS) lobectomies have been available to lung cancer surgeons for two decades. Despite the benefits, only 30 to 40 percent of lobectomies in the U.S. are performed using a minimally invasive technique. And yet, compared with open surgery, lobectomies performed by the VATS approach result in a shorter length of hospital stay, fewer adverse events, less cost to the hospital, and better quality of life for the patient. Read More
In 2015, surgeons in the Lung Transplant Program at Brigham and Women’s Hospital performed 26 lung transplants. After significant investments in surgical staff, quality and processes, the program tripled its volume over a two-year period, performing 75 lung transplants in 2017. During this period of rapid growth, many outcomes were also improved, including a decrease in the length of hospital stay from 24 days (2015) to approximately 15 days (2017) and increased one-year survival to over 90 percent. Read More
A novel platform is showing the potential for combining artificial intelligence (AI) and CT technology to identify disease stage in people with COPD and predict who are most likely to have acute respiratory disorder events and high mortality.
The Severe Asthma Program, part of the Partners Asthma Center, offers state-of-the-art diagnostic and therapeutic options that enable your patients with severe asthma to achieve improved respiratory health. Meanwhile, Brigham and Women’s Hospital researchers are discovering new therapies to manage the disease.
Research points to immunological differences in responses to steroids in patients with severe asthma, suggesting reasons corticosteroids may paradoxically perpetuate inflammation in severe asthma. Read More
Brigham and Women’s Hospital (BWH) researchers have identified new genetic markers associated with chronic obstructive pulmonary disease (COPD). The discovery has shed light on the genetic basis for the disease. Read More